Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic

Int J Pharm. 2021 Dec 15:610:121212. doi: 10.1016/j.ijpharm.2021.121212. Epub 2021 Oct 20.

Abstract

While classic vaccines have proved greatly efficacious in eliminating serious infectious diseases, innovative vaccine platforms open a new pathway to overcome dangerous pandemics via the development of safe and effective formulations. Such platforms play a key role either as antigen delivery systems or as immune-stimulators that induce both innate and adaptive immune responses. Liposomes or lipid nanoparticles, virus-like particles, nanoemulsions, polymeric or inorganic nanoparticles, as well as viral vectors, all belong to the nanoscale and are the main categories of innovative vaccines that are currently on the market or in clinical and preclinical phases. In this paper, we review the above formulations used in vaccinology and we discuss their connection with the development of safe and effective prophylactic vaccines against SARS-CoV-2.

Keywords: Adjuvant; Antigen delivery system; COVID-19; Nanovaccine; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Communicable Diseases*
  • Humans
  • Liposomes
  • Nanoparticles
  • Pandemics / prevention & control
  • SARS-CoV-2
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Lipid Nanoparticles
  • Liposomes
  • Vaccines